Kuroki Tamotsu, Tajima Yoshitsugu, Kanematsu Takashi
Department of Surgery, Nagasaki University, Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Surg Today. 2004;34(12):981-6. doi: 10.1007/s00595-004-2858-6.
Pancreatic cancer is a disease with a dismal outcome and a 5-year survival rate of under 5%. Recent studies have shown that pancreatic cancer consists of an accumulation of genetic and epigenetic alterations during tumor development as in other human cancers. Therefore, new diagnostic methods for early detection and more effective therapeutic strategies based on a better understanding of the molecular biology of pancreatic cancer are urgently required. Recently, promoter hypermethylation of cancer-related genes has emerged as an important mechanism in carcinogenesis. The present review summarizes an overview of the alterations of promoter hypermethylation in pancreatic cancer, and suggests that the further study of promoter hypermethylation involvement in pancreatic cancer and the delineation of molecular mechanisms involved may lead to an improvement in the outcome of this aggressive disease.
胰腺癌是一种预后很差的疾病,5年生存率低于5%。最近的研究表明,与其他人类癌症一样,胰腺癌在肿瘤发生过程中是由遗传和表观遗传改变的积累所构成。因此,迫切需要基于对胰腺癌分子生物学的更好理解而开发新的早期诊断方法和更有效的治疗策略。最近,癌症相关基因的启动子高甲基化已成为致癌作用中的一种重要机制。本综述总结了胰腺癌中启动子高甲基化改变的概况,并表明进一步研究启动子高甲基化在胰腺癌中的作用以及所涉及的分子机制,可能会改善这种侵袭性疾病的预后。